The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 28th 2025
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.
Super-Refractory Status Epilepticus Linked With Unknown Etiologies, High Mortality Rates
September 23rd 2023Patients treated for more than 28 days had a higher chance of status epilepticus cessation, but also a high risk of moderate to severe disability at discharge, according to one study.
Read More
Study Highlights Association of COPD and CVDs, Need for Prevention and Management
September 22nd 2023Among adults 40 years and older with chronic obstructive pulmonary disease (COPD), there is a higher prevalence of cardiovascular diseases (CVDs) compared with a general population without COPD.
Read More
Dr Meredith McKean Shares New Melanoma Studies, Treatment Developments
September 22nd 2023Meredith McKean, MD, MPH, the associate director of the Sarah Cannon Research Institute's Melanoma and Skin Cancer Research Program at Tennessee Oncology, discussed new melanoma studies and treatment developments.
Watch
Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL
September 21st 2023Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.
Read More
First-Line Sacituzumab Govitecan Plus Pembrolizumab Shows Promising Early Activity in NSCLC
September 20th 2023In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small cell lung cancer (NSCLC).
Read More
Despite Treatment Improvements, Second Primary Malignancies Adversely Affect MM Prognosis
September 20th 2023In a real-world study using data from patients diagnosed with multiple myeloma between 2009 and 2021, second primary malignancies adversely impacted survival outcomes in the modern era of therapeutics.
Read More
Dr Erin Gillaspie Explains How to Discover Best Treatments for Patients With Lung Cancer
September 20th 2023Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, explained what testing needs to be done to identify the best treatment for patients with lung cancer.
Watch
Adalimumab Plus Surgery Delivers Better Outcomes Than Adalimumab Alone for HS
September 19th 2023Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with adalimumab alone.
Read More
Relative Benefit in Survival, Reduction in TE/MAVE Risk With Eculizumab for Patients With PNH
September 19th 2023When patients with paroxysmal nocturnal hemoglobinuria (PNH) received eculizumab, survival rates increased and thromboembolic events/major adverse vascular events (TE/MAVE) decreased.
Read More